Skip to content

A study about the Effect of Hydrogen Inhalation on Patients with type III chronic prostatitis/ chronic pelvic pain syndrome

A study about the Effect of Hydrogen Inhalation on Patients with type III chronic prostatitis/ chronic pelvic pain syndrome

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030120
Enrollment
Unknown
Registered
2020-02-23
Start date
2020-03-09
Completion date
Unknown
Last updated
2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type III chronic prostatitis/chronic pelvic pain syndrome

Interventions

Sponsors

Shenzhen Luohu People's Hospital (The Third Affiliated Hospital of Shenzhen University)
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
25 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily participate in the trial and sign a written informed consent form; 2. Aged between 25 and 55 years old (including 25 and 55 years old); 3. Perineal region has obvious pain and discomfort symptoms, and can also accompanied by urinary tract, urinary tract bifurcation and lower urinary tract symptoms, and all symptoms have continued for more than 3 months; 4. Patients with NIH-CPSI (National Institutes of Health Chronic Prostatitis Symptom Index) > 15 points, including pain score > 3 points; 5. The WBC count is more than 10/HP in prostatic fluid examination.

Exclusion criteria

Exclusion criteria: 1. Patient has been diagnosed with severe respiratory dysfunction or required oxygen therapy; 2. Patient with serious diseases of other systems such as severe cardiovascular disease, acute stroke, malignant tumor, severe mental illness, etc.; 3. The investigator judges any disease other than type III chronic prostatitis/chronic pelvic pain syndrome that can cause urinary symptoms or changes in urinary flow rate (eg, neurogenic bladder, bladder neck fibrosis, bladder tumor, urinary calculi, urethral stricture, phimosis or penis tumor, prostatic hyperplasia, prostate cancer, acute and chronic urinary tract infection, acute and chronic renal failure, large (>5 cm) bladder diverticula, etc.); 4. Patient has participated in other clinical trial within 30 days; 5. Patients with poor compliance and failure to complete the trial according to the protocol; 6. Other situations that researchers think the patient is not suitable for the research.

Design outcomes

Primary

MeasureTime frame
NIH-CPSI (National Institutes of Health Chronic Prostatitis Symptom Index);Visual Analog Scale;Quality of Life (QoL) Score;

Secondary

MeasureTime frame
IIEF-5;WBC count in prostatic fluid examination;

Countries

China

Contacts

Public ContactYing Huang

Shenzhen Luohu People's Hospital (The Third Affiliated Hospital of Shenzhen University)

13798381635@163.com+86 13798381635

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026